Since the 2004 KDOQI Guideline 1 was published, there has been an increasing trend towards tailoring antihypertensive therapy to the individual patient, taking into account issues such as the presence or absence of high urine albumin excretion, co-morbidities, concomitant medications, adverse effects, and availability of the agents.
← all excerpts
Chapter 2: Lifestyle and pharmacological treatments for lowering blood pressure in CKD ND patients.
1
—
—